|Bid||0.91 x 100|
|Ask||0.97 x 600|
|Day's Range||1.00 - 1.16|
|52 Week Range||0.83 - 3.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 2, 2018 - Apr 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
–100% of patients have now met the primary endpoint in achieving≥ 50% clinical response with MAT2203–. –Study has met predetermined statistical endpoint for success–. –All patients have elected to continue ...
BEDMINSTER, N.J., Dec. 14, 2017-- Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced the appointment ...
NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Matinas BioPharma Holdings, Inc. (NYSE American: MTNB ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, ...